Skip to main content
Top
Published in: Globalization and Health 1/2010

Open Access 01-12-2010 | Review

Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these?

Authors: Nina Veenstra, Alan Whiteside, David Lalloo, Andrew Gibbs

Published in: Globalization and Health | Issue 1/2010

Login to get access

Abstract

Adherence to antiretroviral therapy is essential for maximising individual treatment outcomes and preventing the development of drug resistance. It is, however, frequently compromised due to predictable, but adverse, scenarios in the countries most severely affected by HIV/AIDS. This paper looks at lessons from three specific crises in southern Africa: the 2008 floods in Mozambique, the ongoing political and economic crisis in Zimbabwe, and the 2007 public sector strike in South Africa. It considers how these crises impacted on the delivery of antiretroviral therapy and looks at some of the strategies employed to mitigate any adverse effects. Based on this it makes recommendations for keeping patients on treatment and limiting the development of drug resistance where treatment interruptions are inevitable.
Literature
1.
go back to reference Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Journal of the American Medical Association. 2006, 296: 679-690. 10.1001/jama.296.6.679.CrossRefPubMed Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Journal of the American Medical Association. 2006, 296: 679-690. 10.1001/jama.296.6.679.CrossRefPubMed
2.
go back to reference Hawkins C, Murphy R: Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS. 2007, 21: 1041-1042. 10.1097/QAD.0b013e3281900eb9.CrossRefPubMed Hawkins C, Murphy R: Adherence to antiretroviral therapy in resource-limited settings: everything matters. AIDS. 2007, 21: 1041-1042. 10.1097/QAD.0b013e3281900eb9.CrossRefPubMed
3.
go back to reference Iliyasu Z, Kabir M, Abubakar IS, Babashani M, Zubair ZA: Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Nigerian Journal of Medicine. 2005, 14: 290-294.PubMed Iliyasu Z, Kabir M, Abubakar IS, Babashani M, Zubair ZA: Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Nigerian Journal of Medicine. 2005, 14: 290-294.PubMed
4.
go back to reference van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE: Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005, 10: 464-470. 10.1111/j.1365-3156.2005.01409.x.CrossRefPubMed van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE: Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005, 10: 464-470. 10.1111/j.1365-3156.2005.01409.x.CrossRefPubMed
5.
go back to reference Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, M'Bangue M, Joko A, Rozenbaum W, Ntone FN, Delaporte E: Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005, 41: 108-111. 10.1086/430712.CrossRefPubMed Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, M'Bangue M, Joko A, Rozenbaum W, Ntone FN, Delaporte E: Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis. 2005, 41: 108-111. 10.1086/430712.CrossRefPubMed
6.
go back to reference Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, Kwasa R, Maridadi J, Moroka TM, Moyo S, Nakiyemba A, Nsimba S, Ogenyi R, Oyabba T, Temu F, Laing R: Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007, 19: 658-665. 10.1080/09540120701244943.CrossRefPubMed Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, Kwasa R, Maridadi J, Moroka TM, Moyo S, Nakiyemba A, Nsimba S, Ogenyi R, Oyabba T, Temu F, Laing R: Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007, 19: 658-665. 10.1080/09540120701244943.CrossRefPubMed
7.
go back to reference Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, Kebaabetswe P, Dickenson D, Mompati K, Essex M, Marlink R: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003, 34: 281-288. 10.1097/00126334-200311010-00004.CrossRefPubMed Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, Kebaabetswe P, Dickenson D, Mompati K, Essex M, Marlink R: Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003, 34: 281-288. 10.1097/00126334-200311010-00004.CrossRefPubMed
8.
go back to reference Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR: Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005, 16: 38-41. 10.1258/0956462052932548.CrossRefPubMed Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR: Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS. 2005, 16: 38-41. 10.1258/0956462052932548.CrossRefPubMed
9.
go back to reference Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, Shah R, Shao HJ, Morpeth SC, McNeill JD, Shao JF, Bartlett JA, Crump JA: Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007, 45: 1492-1498. 10.1086/522991.CrossRefPubMed Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, Shah R, Shao HJ, Morpeth SC, McNeill JD, Shao JF, Bartlett JA, Crump JA: Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007, 45: 1492-1498. 10.1086/522991.CrossRefPubMed
10.
go back to reference Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C: Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006, 3: e438-10.1371/journal.pmed.0030438.PubMedCentralCrossRefPubMed Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C: Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006, 3: e438-10.1371/journal.pmed.0030438.PubMedCentralCrossRefPubMed
11.
go back to reference Gross R, Yip B, Lo Re V, Wood E, Alexander CS, Harrigan PR, Bangsberg DR, Montaner JS, Hogg RS: A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006, 194: 1108-1114. 10.1086/507680.CrossRefPubMed Gross R, Yip B, Lo Re V, Wood E, Alexander CS, Harrigan PR, Bangsberg DR, Montaner JS, Hogg RS: A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006, 194: 1108-1114. 10.1086/507680.CrossRefPubMed
12.
go back to reference Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, Kaplan AH: Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006, 41: 315-322. 10.1097/01.qai.0000197071.77482.6e.CrossRefPubMed Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, Kaplan AH: Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006, 41: 315-322. 10.1097/01.qai.0000197071.77482.6e.CrossRefPubMed
13.
go back to reference Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M, Suter F: Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005, 40: 158-163. 10.1086/426595.CrossRefPubMed Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, Airoldi M, Suter F: Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005, 40: 158-163. 10.1086/426595.CrossRefPubMed
14.
go back to reference Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007, 146: 564-573.CrossRefPubMed Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007, 146: 564-573.CrossRefPubMed
15.
go back to reference Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA: Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007, 44: 30-37. 10.1097/01.qai.0000248351.10383.b7.PubMedCentralCrossRefPubMed Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA: Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007, 44: 30-37. 10.1097/01.qai.0000248351.10383.b7.PubMedCentralCrossRefPubMed
16.
go back to reference Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, Holmes KK: Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004, 15: 803-810. 10.1258/0956462042563666.CrossRefPubMed Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, Holmes KK: Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004, 15: 803-810. 10.1258/0956462042563666.CrossRefPubMed
17.
go back to reference Mannheimer S, Friedland G, Matts J, Child C, Chesney M: The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002, 34: 1115-1121. 10.1086/339074.CrossRefPubMed Mannheimer S, Friedland G, Matts J, Child C, Chesney M: The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002, 34: 1115-1121. 10.1086/339074.CrossRefPubMed
18.
go back to reference Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS: The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004, 35: 261-268. 10.1097/00126334-200403010-00006.CrossRefPubMed Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS: The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004, 35: 261-268. 10.1097/00126334-200403010-00006.CrossRefPubMed
19.
go back to reference Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.CrossRefPubMed Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.CrossRefPubMed
20.
go back to reference Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS: Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002, 16: 1051-1058. 10.1097/00002030-200205030-00012.CrossRefPubMed Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS: Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002, 16: 1051-1058. 10.1097/00002030-200205030-00012.CrossRefPubMed
21.
go back to reference Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006, 43: 78-84. 10.1097/01.qai.0000225015.43266.46.CrossRefPubMed Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006, 43: 78-84. 10.1097/01.qai.0000225015.43266.46.CrossRefPubMed
22.
go back to reference Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Journal of the American Medical Association. 2006, 296: 782-793. 10.1001/jama.296.7.782.CrossRefPubMed Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. Journal of the American Medical Association. 2006, 296: 782-793. 10.1001/jama.296.7.782.CrossRefPubMed
23.
go back to reference van Sighem AI, Wiel van de MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F: Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003, 17: 2227-2236. 10.1097/00002030-200310170-00011.CrossRefPubMed van Sighem AI, Wiel van de MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F: Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003, 17: 2227-2236. 10.1097/00002030-200310170-00011.CrossRefPubMed
24.
go back to reference Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM: Preventing antiretroviral anarchy in sub-Saharan Africa. The Lancet. 2001, 358: 410-414. 10.1016/S0140-6736(01)05551-9.CrossRef Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM: Preventing antiretroviral anarchy in sub-Saharan Africa. The Lancet. 2001, 358: 410-414. 10.1016/S0140-6736(01)05551-9.CrossRef
25.
go back to reference Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008, 13 (Suppl 2): 25-36.PubMed Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008, 13 (Suppl 2): 25-36.PubMed
26.
go back to reference Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007, 21: 965-971. 10.1097/QAD.0b013e32802e6bfa.CrossRefPubMed Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR: Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007, 21: 965-971. 10.1097/QAD.0b013e32802e6bfa.CrossRefPubMed
27.
go back to reference Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC: Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006, 42: 252-259. 10.1086/499044.CrossRefPubMed Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC: Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006, 42: 252-259. 10.1086/499044.CrossRefPubMed
28.
go back to reference Ahern M, Kovats RS, Wilkinson P, Few R, Matthies F: Global health impacts of floods: epidemiologic evidence. Epidemiol Rev. 2005, 27: 36-46. 10.1093/epirev/mxi004.CrossRefPubMed Ahern M, Kovats RS, Wilkinson P, Few R, Matthies F: Global health impacts of floods: epidemiologic evidence. Epidemiol Rev. 2005, 27: 36-46. 10.1093/epirev/mxi004.CrossRefPubMed
30.
go back to reference World Health Organisation: Health actions during flooding in southern Africa. 2008, Southern African Humanitarian Crisis Situation Reports World Health Organisation: Health actions during flooding in southern Africa. 2008, Southern African Humanitarian Crisis Situation Reports
34.
go back to reference Physicians for Human Rights: Health in ruins: a man-made disaster in Zimbabwe. 2009, Cambridge: Physicians for Human Rights Physicians for Human Rights: Health in ruins: a man-made disaster in Zimbabwe. 2009, Cambridge: Physicians for Human Rights
39.
go back to reference Sidley P: Strike cripples health services in South Africa. Br Med J. 2007, 334: 1240-1241. 10.1136/bmj.39245.485579.DB.CrossRef Sidley P: Strike cripples health services in South Africa. Br Med J. 2007, 334: 1240-1241. 10.1136/bmj.39245.485579.DB.CrossRef
43.
go back to reference International Commission on Intervention and State Sovereignty: The Responsibility to Protect. 2001, Ottawa: International Development Research Centre International Commission on Intervention and State Sovereignty: The Responsibility to Protect. 2001, Ottawa: International Development Research Centre
44.
go back to reference Human Rights Watch: Discrimination, denial, and deportation: human rights abuses affecting migrants living with HIV. 2009, New York: Human Rights Watch Human Rights Watch: Discrimination, denial, and deportation: human rights abuses affecting migrants living with HIV. 2009, New York: Human Rights Watch
Metadata
Title
Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these?
Authors
Nina Veenstra
Alan Whiteside
David Lalloo
Andrew Gibbs
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2010
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/1744-8603-6-4

Other articles of this Issue 1/2010

Globalization and Health 1/2010 Go to the issue